메뉴 건너뛰기




Volumn 68, Issue 8, 2008, Pages 1089-1103

Improving delivery of aminosalicylates in ulcerative colitis: Effect on patient outcomes

Author keywords

Aminosalicylic acids, therapeutic use; Balsalazide, therapeutic use; Mesalazine, therapeutic use; Olsalazine, therapeutic use; Ulcerative colitis, treatment

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; BALSALAZIDE; DIVISTYRAMINE; ETHYL CELLULOSE; EUDRAGIT; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

EID: 43749118171     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00006     Document Type: Review
Times cited : (27)

References (108)
  • 2
    • 43749105471 scopus 로고    scopus 로고
    • Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis: B. Therapeutic results in ulcerative colitis: C. Toxic manifestations in treatments with sulfanilamide preparation. Acta Medica Scandinavia 1942; 110: 557-90
    • Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis: B. Therapeutic results in ulcerative colitis: C. Toxic manifestations in treatments with sulfanilamide preparation. Acta Medica Scandinavia 1942; 110: 557-90
  • 3
    • 50549187947 scopus 로고
    • Sulphasalazine and salicylazosulphadimidine in ulcerative colitis
    • Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; I: 1094-6
    • (1962) Lancet , vol.1 , pp. 1094-1096
    • Baron, J.H.1    Connell, A.M.2    Lennard-Jones, J.E.3
  • 4
    • 84920223116 scopus 로고
    • An experiment to determine the active therapeutic moiety of sulphasalazine
    • Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; II: 892-5
    • (1977) Lancet , vol.2 , pp. 892-895
    • Azad Khan, A.K.1    Piris, J.2    Truelove, S.C.3
  • 5
    • 0018961746 scopus 로고
    • Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine
    • van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632-5
    • (1980) Gut , vol.21 , pp. 632-635
    • van Hees, P.A.1    Bakker, J.H.2    van Tongeren, J.H.3
  • 6
    • 0019204911 scopus 로고
    • Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease
    • Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980; 303: 1499-502
    • (1980) N Engl J Med , vol.303 , pp. 1499-1502
    • Klotz, U.1    Maier, K.2    Fischer, C.3
  • 7
    • 0022541706 scopus 로고
    • Pharmacological and biochemical actions of sulphasalazine
    • Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs 1986; 32 Suppl. 1: 18-26
    • (1986) Drugs , vol.32 , Issue.SUPPL. 1 , pp. 18-26
    • Hoult, J.R.1
  • 8
    • 0015348162 scopus 로고
    • The role of intestinal bacteria in the metabolism of salicylazosulfapyridine
    • Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181: 555-62
    • (1972) J Pharmacol Exp Ther , vol.181 , pp. 555-562
    • Peppercorn, M.A.1    Goldman, P.2
  • 9
    • 0015374469 scopus 로고
    • Absorption, metabolism, and excretion of salicylazosulfapyridine in man
    • Schroder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539-51
    • (1972) Clin Pharmacol Ther , vol.13 , pp. 539-551
    • Schroder, H.1    Campbell, D.E.2
  • 10
    • 0015916139 scopus 로고
    • Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype
    • Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491-5
    • (1973) N Engl J Med , vol.289 , pp. 491-495
    • Das, K.M.1    Eastwood, M.A.2    McManus, J.P.3
  • 11
    • 0020964483 scopus 로고
    • Sulfasalazine: Adverse effects and desensitization
    • Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42
    • (1983) Dig Dis Sci , vol.28 , pp. 833-842
    • Taffet, S.L.1    Das, K.M.2
  • 12
    • 2542553386 scopus 로고    scopus 로고
    • Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: A randomized, single-dose, crossover study in healthy volunteers
    • Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther 2004; 19: 1089-98
    • (2004) Aliment Pharmacol Ther , vol.19 , pp. 1089-1098
    • Sandborn, W.J.1    Hanauer, S.B.2    Buch, A.3
  • 13
    • 0033636562 scopus 로고    scopus 로고
    • Progress in understanding the mechanisms of action of 5-aminosalicylic acid
    • MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000; 95: 3343-5
    • (2000) Am J Gastroenterol , vol.95 , pp. 3343-3345
    • MacDermott, R.P.1
  • 14
    • 0028985095 scopus 로고
    • 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells
    • Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272: 399-406
    • (1995) J Pharmacol Exp Ther , vol.272 , pp. 399-406
    • Stevens, C.1    Lipman, M.2    Fabry, S.3
  • 15
    • 0027414728 scopus 로고
    • Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: A novel mechanism of action of sulphasalazine
    • Greenfield SM, Hamblin AS, Shakoor ZS, et al. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut 1993; 34: 252-6
    • (1993) Gut , vol.34 , pp. 252-256
    • Greenfield, S.M.1    Hamblin, A.S.2    Shakoor, Z.S.3
  • 16
    • 0025306675 scopus 로고
    • Characteristics of immune-complex-induced chronic experimental colitis in rats with a therapeutic effect of sulphasalazine
    • Axelsson LG, Ahlstedt S. Characteristics of immune-complex-induced chronic experimental colitis in rats with a therapeutic effect of sulphasalazine. Scand J Gastroenterol 1990; 25: 203-9
    • (1990) Scand J Gastroenterol , vol.25 , pp. 203-209
    • Axelsson, L.G.1    Ahlstedt, S.2
  • 18
    • 0023192364 scopus 로고
    • Inhibition of neutrophil degranulation and superoxide production by sulfasalazine: Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine
    • Neal TM, Winterbourn CC, Vissers MC. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine: comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol 1987; 36: 2765-8
    • (1987) Biochem Pharmacol , vol.36 , pp. 2765-2768
    • Neal, T.M.1    Winterbourn, C.C.2    Vissers, M.C.3
  • 19
    • 0033021470 scopus 로고    scopus 로고
    • Oral delayed-release mesalazine: A review of its use in ulcerative colitis and Crohn's disease
    • Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999; 57: 383-408
    • (1999) Drugs , vol.57 , pp. 383-408
    • Prakash, A.1    Markham, A.2
  • 20
    • 4243762722 scopus 로고
    • Sulfasalazine inhibits cytokine production in human mononuclear cells: A novel anti-inflammatory mechanism
    • Cominelli FZCA, Dinarello CA. Sulfasalazine inhibits cytokine production in human mononuclear cells: a novel anti-inflammatory mechanism. Gastroenterology 1992; 96: A96
    • (1992) Gastroenterology , vol.96
    • Cominelli, F.Z.C.A.1    Dinarello, C.A.2
  • 21
    • 0026081338 scopus 로고
    • 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease
    • Mahida YR, Lamming CE, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50-4
    • (1991) Gut , vol.32 , pp. 50-54
    • Mahida, Y.R.1    Lamming, C.E.2    Gallagher, A.3
  • 22
    • 0026637266 scopus 로고
    • Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation
    • Rachmilewitz D, Karmeli F, Schwartz LW, et al. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 929-32
    • (1992) Gut , vol.33 , pp. 929-932
    • Rachmilewitz, D.1    Karmeli, F.2    Schwartz, L.W.3
  • 23
    • 0025252493 scopus 로고
    • Sulfasalazine inhibits the binding of TNF alpha to its receptor
    • Shanahan F, Niederlehner A, Carramanzana N, et al. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990; 20: 217-24
    • (1990) Immunopharmacology , vol.20 , pp. 217-224
    • Shanahan, F.1    Niederlehner, A.2    Carramanzana, N.3
  • 24
    • 0017231844 scopus 로고
    • Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites
    • Collier HO, Francis AA, McDonald-Gibson WJ, et al. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins 1976; 11: 219-25
    • (1976) Prostaglandins , vol.11 , pp. 219-225
    • Collier, H.O.1    Francis, A.A.2    McDonald-Gibson, W.J.3
  • 25
    • 0018084814 scopus 로고
    • Role of prostaglandins in ulcerative colitis: Enhanced production during active disease and inhibition by sulfasalazine
    • Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638-40
    • (1978) Gastroenterology , vol.75 , pp. 638-640
    • Sharon, P.1    Ligumsky, M.2    Rachmilewitz, D.3
  • 26
    • 0026788063 scopus 로고
    • Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: Effects of conventional and potential new therapies
    • Gertner DJ, Rampton DS, de Nucci G, et al. Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: effects of conventional and potential new therapies. European J Gastroenterol hepatol 1992; 4: 837-41
    • (1992) European J Gastroenterol hepatol , vol.4 , pp. 837-841
    • Gertner, D.J.1    Rampton, D.S.2    de Nucci, G.3
  • 27
    • 0025886411 scopus 로고
    • Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes
    • Horn H, Preclik G, Stange EF, et al. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand J Gastroenterol 1991; 26: 867-79
    • (1991) Scand J Gastroenterol , vol.26 , pp. 867-879
    • Horn, H.1    Preclik, G.2    Stange, E.F.3
  • 28
    • 0029548254 scopus 로고    scopus 로고
    • The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells
    • Schmidt C, Fels T, Baumeister B, et al. The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells. Curr Med Res Opin 1996; 13: 417-25
    • (1996) Curr Med Res Opin , vol.13 , pp. 417-425
    • Schmidt, C.1    Fels, T.2    Baumeister, B.3
  • 29
    • 33747777758 scopus 로고    scopus 로고
    • PPARγ as a new therapeutic target in inflammatory bowel diseases
    • Dubuquoy L, Rousseaux C, Thuru X, et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341-9
    • (2006) Gut , vol.55 , pp. 1341-1349
    • Dubuquoy, L.1    Rousseaux, C.2    Thuru, X.3
  • 30
    • 0032032469 scopus 로고    scopus 로고
    • Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
    • Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163-74
    • (1998) J Clin Invest , vol.101 , pp. 1163-1174
    • Wahl, C.1    Liptay, S.2    Adler, G.3
  • 31
    • 0025851574 scopus 로고
    • Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation
    • Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991; 36: 174-8
    • (1991) Dig Dis Sci , vol.36 , pp. 174-178
    • Gionchetti, P.1    Guarnieri, C.2    Campieri, M.3
  • 32
    • 0026075998 scopus 로고
    • Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid
    • Greenfield SM, Punchard NA, Thompson RP. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid. Gut 1991; 32: 1156-9
    • (1991) Gut , vol.32 , pp. 1156-1159
    • Greenfield, S.M.1    Punchard, N.A.2    Thompson, R.P.3
  • 33
    • 0036897124 scopus 로고    scopus 로고
    • Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis
    • Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol 2002; 97: 2939-41
    • (2002) Am J Gastroenterol , vol.97 , pp. 2939-2941
    • Sandborn, W.J.1
  • 34
    • 33744817063 scopus 로고    scopus 로고
    • Treatment of ulcerative colitis with oral mesalamine: Advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention
    • Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord 2006; 6: 97-105
    • (2006) Rev Gastroenterol Disord , vol.6 , pp. 97-105
    • Sandborn, W.J.1
  • 35
    • 18444418282 scopus 로고    scopus 로고
    • Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis
    • Forbes A, Al-Damluji A, Ashworth S, et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 1099-104
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 1099-1104
    • Forbes, A.1    Al-Damluji, A.2    Ashworth, S.3
  • 36
    • 13644267728 scopus 로고    scopus 로고
    • A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis
    • Marakhouski Y, Fixa B, Holoman J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 133-40
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 133-140
    • Marakhouski, Y.1    Fixa, B.2    Holoman, J.3
  • 37
    • 0025011866 scopus 로고
    • Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man
    • Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 523-33
    • (1990) Aliment Pharmacol Ther , vol.4 , pp. 523-533
    • Christensen, L.A.1    Fallingborg, J.2    Abildgaard, K.3
  • 39
    • 0032801475 scopus 로고    scopus 로고
    • Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease
    • Ewe K, Schwartz S, Petersen S, et al. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci 1999; 44: 1434-9
    • (1999) Dig Dis Sci , vol.44 , pp. 1434-1439
    • Ewe, K.1    Schwartz, S.2    Petersen, S.3
  • 40
    • 0024949034 scopus 로고
    • pH-profile and regional transit times of the normal gut measured by a radiotelemetry device
    • Fallingborg J, Christensen LA, Ingeman-Nielsen M, et al. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989; 3: 605-13
    • (1989) Aliment Pharmacol Ther , vol.3 , pp. 605-613
    • Fallingborg, J.1    Christensen, L.A.2    Ingeman-Nielsen, M.3
  • 41
    • 0035084176 scopus 로고    scopus 로고
    • Intestinal luminal pH remisin inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs
    • Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH remisin inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48: 571-7
    • (2001) Gut , vol.48 , pp. 571-577
    • Nugent, S.G.1    Kumar, D.2    Rampton, D.S.3
  • 42
    • 43749111667 scopus 로고    scopus 로고
    • Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA containing capsules [abstract]
    • Nugent SG, Kumar D, Rampton DS, et al. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA containing capsules [abstract]. Gut 1999; 47
    • (1999) Gut , pp. 47
    • Nugent, S.G.1    Kumar, D.2    Rampton, D.S.3
  • 43
    • 0031817515 scopus 로고    scopus 로고
    • Gastrointestinal pH profiles in patients with inflammatory bowel disease
    • Press AG, Hauptmann IA, Hauptmann L, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12: 673-8
    • (1998) Aliment Pharmacol Ther , vol.12 , pp. 673-678
    • Press, A.G.1    Hauptmann, I.A.2    Hauptmann, L.3
  • 44
    • 33846213645 scopus 로고    scopus 로고
    • Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
    • quiz 432-3
    • Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75; quiz 432-3
    • (2007) Gastroenterology , vol.132 , pp. 66-75
    • Kamm, M.A.1    Sandborn, W.J.2    Gassull, M.3
  • 45
    • 33846242590 scopus 로고    scopus 로고
    • Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    • Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 95-102
    • Lichtenstein, G.R.1    Kamm, M.A.2    Boddu, P.3
  • 46
    • 0028934947 scopus 로고
    • Delivery and fate of oral mesalamine microgranules within the human small intestine
    • Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 1427-33
    • (1995) Gastroenterology , vol.108 , pp. 1427-1433
    • Layer, P.H.1    Goebell, H.2    Keller, J.3
  • 47
    • 0029002573 scopus 로고
    • Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine
    • Larouche J, Morais J, Picard M, et al. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment Pharmacol Ther 1995; 9: 315-20
    • (1995) Aliment Pharmacol Ther , vol.9 , pp. 315-320
    • Larouche, J.1    Morais, J.2    Picard, M.3
  • 48
    • 0036325459 scopus 로고    scopus 로고
    • Balsalazide: A review of its therapeutic use in mild-to-moderate ulcerative colitis
    • Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs 2002; 62: 1689-705
    • (2002) Drugs , vol.62 , pp. 1689-1705
    • Muijsers, R.B.1    Goa, K.L.2
  • 49
    • 0024433044 scopus 로고
    • Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: A randomised double blind trial
    • Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 1989; 30: 1354-61
    • (1989) Gut , vol.30 , pp. 1354-1361
    • Feurle, G.E.1    Theuer, D.2    Velasco, S.3
  • 50
    • 0023921849 scopus 로고
    • Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis
    • Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835-7
    • (1988) Gut , vol.29 , pp. 835-837
    • Ireland, A.1    Mason, C.H.2    Jewell, D.P.3
  • 51
    • 7344238541 scopus 로고    scopus 로고
    • Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis
    • Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 707-15
    • (1998) Aliment Pharmacol Ther , vol.12 , pp. 707-715
    • Kruis, W.1    Brandes, J.W.2    Schreiber, S.3
  • 52
    • 0028071107 scopus 로고
    • Optimum dose of olsalazine for maintaining remission in ulcerative colitis
    • Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282-6
    • (1994) Gut , vol.35 , pp. 1282-1286
    • Travis, S.P.1    Tysk, C.2    de Silva, H.J.3
  • 53
    • 0018461754 scopus 로고
    • Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin)
    • van Hees PA, Tuinte JH, van Rossum JM, et al. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut 1979; 20: 300-4
    • (1979) Gut , vol.20 , pp. 300-304
    • van Hees, P.A.1    Tuinte, J.H.2    van Rossum, J.M.3
  • 54
    • 0020441780 scopus 로고
    • Azo reduction of sulphasalazine in healthy volunteers
    • Houston JB, Day J, Walker J. Azo reduction of sulphasalazine in healthy volunteers. Br J Clin Pharmacol 1982; 14: 395-8
    • (1982) Br J Clin Pharmacol , vol.14 , pp. 395-398
    • Houston, J.B.1    Day, J.2    Walker, J.3
  • 55
    • 0033944708 scopus 로고    scopus 로고
    • Putting rectal 5-aminosalicylic acid in its place: The role in distal ulcerative colitis
    • Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-36
    • (2000) Am J Gastroenterol , vol.95 , pp. 1628-1636
    • Marshall, J.K.1    Irvine, E.J.2
  • 56
    • 0033031196 scopus 로고    scopus 로고
    • A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: A randomized controlled multicentre trial
    • Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13: 381-8
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 381-388
    • Gionchetti, P.1    Ardizzone, S.2    Benvenuti, M.E.3
  • 57
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: A randomized study
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317: 1625-9
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 58
    • 0025779674 scopus 로고
    • Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: A multicenter study
    • Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991; 115: 350-5
    • (1991) Ann Intern Med , vol.115 , pp. 350-355
    • Sninsky, C.A.1    Cort, D.H.2    Shanahan, F.3
  • 59
    • 0023920745 scopus 로고
    • Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse
    • Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669-74
    • (1988) Gut , vol.29 , pp. 669-674
    • Riley, S.A.1    Mani, V.2    Goodman, M.J.3
  • 60
    • 0006281157 scopus 로고
    • Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid [letter]
    • Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid [letter]. BMJ (Clin Res Ed) 1982; 285: 1012
    • (1982) BMJ (Clin Res Ed) , vol.285 , pp. 1012
    • Dew, M.J.1    Hughes, P.2    Harries, A.D.3
  • 61
    • 0020560697 scopus 로고
    • Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth
    • Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. BMJ (Clin Res Ed) 1983; 287: 23-4
    • (1983) BMJ (Clin Res Ed) , vol.287 , pp. 23-24
    • Dew, M.J.1    Harries, A.D.2    Evans, N.3
  • 62
    • 0023906720 scopus 로고
    • Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
    • Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-9
    • (1988) Gastroenterology , vol.94 , pp. 1383-1389
    • Riley, S.A.1    Mani, V.2    Goodman, M.J.3
  • 63
    • 0030045124 scopus 로고    scopus 로고
    • An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: A randomized, placebo-controlled trial
    • The Mesalamine Study Group
    • The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 204-11
    • (1996) Ann Intern Med , vol.124 , pp. 204-211
  • 64
    • 18444417417 scopus 로고    scopus 로고
    • Comparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study
    • Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111-9
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 1111-1119
    • Paoluzi, O.A.1    Iacopini, F.2    Pica, R.3
  • 65
    • 0024066430 scopus 로고
    • Delayed-release mesalazine (5-aminosalicylic acid): Coat dissolution and excretion in ileostomy subjects
    • Riley SA, Tavares IA, Bennett A, et al. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol 1988; 26: 173-7
    • (1988) Br J Clin Pharmacol , vol.26 , pp. 173-177
    • Riley, S.A.1    Tavares, I.A.2    Bennett, A.3
  • 66
    • 0027292761 scopus 로고
    • Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group
    • Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97
    • (1993) Am J Gastroenterol , vol.88 , pp. 1188-1197
    • Hanauer, S.1    Schwartz, J.2    Robinson, M.3
  • 67
    • 0028838417 scopus 로고
    • Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis
    • Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995; 30 Suppl. 8: 108-11
    • (1995) J Gastroenterol , vol.30 , Issue.SUPPL. 8 , pp. 108-111
    • Munakata, A.1    Yoshida, Y.2    Muto, T.3
  • 68
    • 0028804562 scopus 로고
    • Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group
    • Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995; 40: 296-304
    • (1995) Dig Dis Sci , vol.40 , pp. 296-304
    • Miner, P.1    Hanauer, S.2    Robinson, M.3
  • 69
    • 0024208726 scopus 로고
    • Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis
    • Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95: 1449-53
    • (1988) Gastroenterology , vol.95 , pp. 1449-1453
    • Mulder, C.J.1    Tytgat, G.N.2    Weterman, I.T.3
  • 70
    • 9044250095 scopus 로고
    • Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group
    • Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995; 7: 1025-30
    • (1995) Eur J Gastroenterol Hepatol , vol.7 , pp. 1025-1030
    • Fockens, P.1    Mulder, C.J.2    Tytgat, G.N.3
  • 71
    • 0036082021 scopus 로고    scopus 로고
    • A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis
    • Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 1398-407
    • (2002) Am J Gastroenterol , vol.97 , pp. 1398-1407
    • Levine, D.S.1    Riff, D.S.2    Pruitt, R.3
  • 72
    • 6844237647 scopus 로고    scopus 로고
    • Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group
    • Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998; 114: 15-22
    • (1998) Gastroenterology , vol.114 , pp. 15-22
    • Green, J.R.1    Lobo, A.J.2    Holdsworth, C.D.3
  • 73
    • 0036897005 scopus 로고    scopus 로고
    • Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis
    • Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 3078-86
    • (2002) Am J Gastroenterol , vol.97 , pp. 3078-3086
    • Pruitt, R.1    Hanson, J.2    Safdi, M.3
  • 74
    • 0036088353 scopus 로고    scopus 로고
    • Equimolar doses of balsalazide and mesalamine: Are we comparing apples and oranges?
    • Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am J Gastroenterol 2002; 97: 1283-5
    • (2002) Am J Gastroenterol , vol.97 , pp. 1283-1285
    • Farrell, R.J.1    Peppercorn, M.A.2
  • 75
    • 0022410980 scopus 로고
    • Olsalazine in active ulcerative colitis
    • Selby WS, Barr GD, Ireland A, et al. Olsalazine in active ulcerative colitis. BMJ (Clin Res Ed) 1985; 291: 1373-5
    • (1985) BMJ (Clin Res Ed) , vol.291 , pp. 1373-1375
    • Selby, W.S.1    Barr, G.D.2    Ireland, A.3
  • 76
    • 0024225057 scopus 로고
    • Olsalazine in the treatment of active ulcerative colitis: A placebo controlled clinical trial and assessment of drug disposition
    • Hetzel DJ, Shearman DJ, Labrooy J, et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scand J Gastroenterol Suppl 1988; 148: 61-9
    • (1988) Scand J Gastroenterol Suppl , vol.148 , pp. 61-69
    • Hetzel, D.J.1    Shearman, D.J.2    Labrooy, J.3
  • 77
    • 0030903812 scopus 로고    scopus 로고
    • Maintenance therapy for inflammatory bowel disease: What really works
    • Sutherland LR. Maintenance therapy for inflammatory bowel disease: what really works. Can J Gastroenterol 1997; 11: 261-4
    • (1997) Can J Gastroenterol , vol.11 , pp. 261-264
    • Sutherland, L.R.1
  • 78
    • 27844526408 scopus 로고    scopus 로고
    • Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis
    • Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-78
    • (1997) Inflamm Bowel Dis , vol.3 , pp. 65-78
    • Sutherland, L.R.1    Roth, D.E.2    Beck, P.L.3
  • 79
    • 0026566566 scopus 로고
    • Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis
    • Courtney MG, Nunes DP, Bergin CF, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339: 1279-81
    • (1992) Lancet , vol.339 , pp. 1279-1281
    • Courtney, M.G.1    Nunes, D.P.2    Bergin, C.F.3
  • 80
    • 0023819344 scopus 로고
    • 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?
    • Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol 1988; 10: 406-9
    • (1988) J Clin Gastroenterol , vol.10 , pp. 406-409
    • Campieri, M.1    Gionchetti, P.2    Belluzzi, A.3
  • 81
    • 0025837516 scopus 로고
    • Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis
    • Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32: 929-31
    • (1991) Gut , vol.32 , pp. 929-931
    • Campieri, M.1    Gionchetti, P.2    Belluzzi, A.3
  • 82
    • 0019467018 scopus 로고
    • Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas
    • Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; II: 270-1
    • (1981) Lancet , vol.2 , pp. 270-271
    • Campieri, M.1    Lanfranchi, G.A.2    Bazzocchi, G.3
  • 83
    • 0022540098 scopus 로고
    • 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: A randomized, controlled trial
    • Friedman LS, Richter JM, Kirkham SE, et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81: 412-8
    • (1986) Am J Gastroenterol , vol.81 , pp. 412-418
    • Friedman, L.S.1    Richter, J.M.2    Kirkham, S.E.3
  • 84
    • 0033944175 scopus 로고    scopus 로고
    • Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis
    • Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000; 95: 1749-54
    • (2000) Am J Gastroenterol , vol.95 , pp. 1749-1754
    • Hanauer, S.1    Good, L.I.2    Goodman, M.W.3
  • 85
    • 0030862269 scopus 로고    scopus 로고
    • Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis
    • Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997; 11: 1053-7
    • (1997) Aliment Pharmacol Ther , vol.11 , pp. 1053-1057
    • Gionchetti, P.1    Rizzello, F.2    Venturi, A.3
  • 86
    • 0027508281 scopus 로고
    • Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: A multicenter comparative trial with 5-ASA enema
    • Campieri M, Paoluzi P, D'Albasio G, et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: a multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993; 38: 1843-50
    • (1993) Dig Dis Sci , vol.38 , pp. 1843-1850
    • Campieri, M.1    Paoluzi, P.2    D'Albasio, G.3
  • 87
    • 0030827118 scopus 로고    scopus 로고
    • A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
    • Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71
    • (1997) Am J Gastroenterol , vol.92 , pp. 1867-1871
    • Safdi, M.1    DeMicco, M.2    Sninsky, C.3
  • 88
    • 0023876851 scopus 로고
    • 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in left-release sided ulcerative colitis
    • Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-release sided ulcerative colitis. Gastroenterology 1988; 94: 1075-9
    • (1988) Gastroenterology , vol.94 , pp. 1075-1079
    • Biddle, W.L.1    Greenberger, N.J.2    Swan, J.T.3
  • 89
    • 0025372322 scopus 로고
    • Long-term use of mesalamine enemas to induce remission in ulcerative colitis
    • Biddle WL, Miner Jr PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990; 99: 113-8
    • (1990) Gastroenterology , vol.99 , pp. 113-118
    • Biddle, W.L.1    Miner Jr, P.B.2
  • 90
    • 0030737685 scopus 로고    scopus 로고
    • Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study
    • d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143-7
    • (1997) Am J Gastroenterol , vol.92 , pp. 1143-1147
    • d'Albasio, G.1    Pacini, F.2    Camarri, E.3
  • 91
    • 0025049819 scopus 로고
    • 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: A double-blind placebo-controlled clinical trial
    • D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990; 85: 1079-82
    • (1990) Am J Gastroenterol , vol.85 , pp. 1079-1082
    • D'Arienzo, A.1    Panarese, A.2    D'Armiento, F.P.3
  • 92
    • 34548603473 scopus 로고    scopus 로고
    • Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a randomized controlled study
    • Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007; 13: 1115-20
    • (2007) Inflamm Bowel Dis , vol.13 , pp. 1115-1120
    • Yokoyama, H.1    Takagi, S.2    Kuriyama, S.3
  • 93
    • 0026784770 scopus 로고
    • Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations
    • De Vos M, Verdievel H, Schoonjans R, et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992; 33: 1338-42
    • (1992) Gut , vol.33 , pp. 1338-1342
    • De Vos, M.1    Verdievel, H.2    Schoonjans, R.3
  • 94
    • 33745042439 scopus 로고    scopus 로고
    • Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
    • CD000543
    • Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (3): CD000543
    • (2006) Cochrane Database Syst Rev , Issue.3
    • Sutherland, L.1    Macdonald, J.K.2
  • 95
    • 33644653559 scopus 로고    scopus 로고
    • Delayed-release oral mesalamine at 4.8 g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial
    • Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85
    • (2005) Am J Gastroenterol , vol.100 , pp. 2478-2485
    • Hanauer, S.B.1    Sandborn, W.J.2    Kornbluth, A.3
  • 96
    • 0035181627 scopus 로고    scopus 로고
    • Low dose balsalazide (1.5g twice daily) and mesalazine (0.5g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0g twice daily) was superior in preventing relapses
    • Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5g twice daily) and mesalazine (0.5g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0g twice daily) was superior in preventing relapses. Gut 2001; 49: 783-9
    • (2001) Gut , vol.49 , pp. 783-789
    • Kruis, W.1    Schreiber, S.2    Theuer, D.3
  • 97
    • 33847723392 scopus 로고    scopus 로고
    • The risks and the benefits of mesalazine as a treatment for ulcerative colitis
    • Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007; 6: 99-107
    • (2007) Expert Opin Drug Saf , vol.6 , pp. 99-107
    • Moss, A.C.1    Peppercorn, M.A.2
  • 98
    • 15944429309 scopus 로고    scopus 로고
    • Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine and mesalamine in rabbit distal ileum
    • Kles KAVS, Turner JR, Musch MW, et al. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine and mesalamine in rabbit distal ileum. Inflamm Bowel Dis 2005; 11: 253-7
    • (2005) Inflamm Bowel Dis , vol.11 , pp. 253-257
    • Kles, K.A.V.S.1    Turner, J.R.2    Musch, M.W.3
  • 99
    • 0025231719 scopus 로고
    • Pancreatitis after rectal administration of 5-aminosalicylic acid
    • Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol 1990; 12: 198-9
    • (1990) J Clin Gastroenterol , vol.12 , pp. 198-199
    • Isaacs, K.L.1    Murphy, D.2
  • 100
    • 0034798909 scopus 로고    scopus 로고
    • Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
    • Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33
    • (2001) Am J Gastroenterol , vol.96 , pp. 2929-2933
    • Kane, S.V.1    Cohen, R.D.2    Aikens, J.E.3
  • 101
    • 0037245392 scopus 로고    scopus 로고
    • Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis
    • Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43
    • (2003) Am J Med , vol.114 , pp. 39-43
    • Kane, S.1    Huo, D.2    Aikens, J.3
  • 102
    • 0042128396 scopus 로고    scopus 로고
    • Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease
    • Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 191-198
    • Shale, M.J.1    Riley, S.A.2
  • 103
    • 0013483122 scopus 로고    scopus 로고
    • A multi-center double-blind placebo-controlled dose ranging trial of olsalazine for mild-moderately active ulcerative colitis [abstract]
    • Hanauer S, Barish C, Pambianco D, et al. A multi-center double-blind placebo-controlled dose ranging trial of olsalazine for mild-moderately active ulcerative colitis [abstract]. Gastroenterology 1996; 110: A921
    • (1996) Gastroenterology , vol.110
    • Hanauer, S.1    Barish, C.2    Pambianco, D.3
  • 104
    • 0344747708 scopus 로고
    • Olsalazine in the treatment of mild to moderate ulcerative colitis [abstract]
    • Robinson M, Gitnick G, Balart L, et al. Olsalazine in the treatment of mild to moderate ulcerative colitis [abstract]. Gastroenterology 1988; 84: A381
    • (1988) Gastroenterology , vol.84
    • Robinson, M.1    Gitnick, G.2    Balart, L.3
  • 105
    • 0025364388 scopus 로고
    • Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis
    • Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990; 85: 562-6
    • (1990) Am J Gastroenterol , vol.85 , pp. 562-566
    • Zinberg, J.1    Molinas, S.2    Das, K.M.3
  • 106
    • 4243950894 scopus 로고    scopus 로고
    • Balsalazide as salvage therapy for mesalamine failure/intolerance in patients with ulcerative colitis
    • Yang Y. Balsalazide as salvage therapy for mesalamine failure/intolerance in patients with ulcerative colitis. Am J Gastroenterol 2001; 90: S313-4
    • (2001) Am J Gastroenterol , vol.90
    • Yang, Y.1
  • 107
    • 0033980980 scopus 로고    scopus 로고
    • Colorectal cancer prevention in ulcerative colitis: A case-control study
    • Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-53
    • (2000) Aliment Pharmacol Ther , vol.14 , pp. 145-153
    • Eaden, J.1    Abrams, K.2    Ekbom, A.3
  • 108
    • 21344446543 scopus 로고    scopus 로고
    • Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies
    • Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53
    • (2005) Am J Gastroenterol , vol.100 , pp. 1345-1353
    • Velayos, F.S.1    Terdiman, J.P.2    Walsh, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.